192 related articles for article (PubMed ID: 29094350)
21. Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience.
Peffault de Latour R; Porcher R; Dalle JH; Aljurf M; Korthof ET; Svahn J; Willemze R; Barrenetxea C; Mialou V; Soulier J; Ayas M; Oneto R; Bacigalupo A; Marsh JC; Peters C; Socie G; Dufour C; ;
Blood; 2013 Dec; 122(26):4279-86. PubMed ID: 24144640
[TBL] [Abstract][Full Text] [Related]
22. Hematopoietic stem cell transplantation for high-risk adult patients with severe aplastic anemia; reduction of graft failure by enhancing stem cell dose.
Min CK; Kim DW; Lee JW; Han CW; Min WS; Kim CC
Haematologica; 2001 Mar; 86(3):303-10. PubMed ID: 11255278
[TBL] [Abstract][Full Text] [Related]
23. Two decades of stem cell transplantation in patients with Fanconi anemia: Analysis of factors affecting transplant outcomes.
Fink O; Even-Or E; Avni B; Grisariu S; Zaidman I; Schejter YD; NaserEddin A; Najajreh M; Stepensky P
Clin Transplant; 2023 Jan; 37(1):e14835. PubMed ID: 36259220
[TBL] [Abstract][Full Text] [Related]
24. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
25. Long-term results of non-fludarabine versus fludarabine-based stem cell transplantation without total body irradiation in Fanconi anemia patients.
Hamidieh AA; Alimoghaddam K; Jahani M; Mousavi SA; Iravani M; Bahar B; Jalili M; Jalali A; Behfar M; Ghavamzadeh A
Hematol Oncol Stem Cell Ther; 2011; 4(3):109-15. PubMed ID: 21982883
[TBL] [Abstract][Full Text] [Related]
26. Transplantation for Fanconi's anaemia: long-term follow-up of fifty patients transplanted from a sibling donor after low-dose cyclophosphamide and thoraco-abdominal irradiation for conditioning.
Socié G; Devergie A; Girinski T; Piel G; Ribaud P; Esperou H; Parquet N; Maarek O; Noguera MH; Richard P; Brison O; Gluckman E
Br J Haematol; 1998 Oct; 103(1):249-55. PubMed ID: 9792317
[TBL] [Abstract][Full Text] [Related]
27. Unrelated donor bone marrow transplantation for Fanconi anemia.
Davies SM; Khan S; Wagner JE; Arthur DC; Auerbach AD; Ramsay NK; Weisdorf DJ
Bone Marrow Transplant; 1996 Jan; 17(1):43-7. PubMed ID: 8673053
[TBL] [Abstract][Full Text] [Related]
28. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
29. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
30. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
[TBL] [Abstract][Full Text] [Related]
31. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
32. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
[TBL] [Abstract][Full Text] [Related]
33. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
34. A single centre experience with allogeneic stem cell transplantation for severe aplastic anaemia in childhood.
Ladenstein R; Peters C; Minkov M; Emminger-Schmidmeier W; Mann G; Höcker P; Hawliczek R; Rosenmayr A; Fink FM; Niederwieser D; Gadner H
Klin Padiatr; 1997; 209(4):201-8. PubMed ID: 9293451
[TBL] [Abstract][Full Text] [Related]
35. Results of unrelated cord blood transplant in fanconi anemia patients: risk factor analysis for engraftment and survival.
Gluckman E; Rocha V; Ionescu I; Bierings M; Harris RE; Wagner J; Kurtzberg J; Champagne MA; Bonfim C; Bittencourt M; Darbyshire P; Fernandez MN; Locatelli F; Pasquini R;
Biol Blood Marrow Transplant; 2007 Sep; 13(9):1073-82. PubMed ID: 17697970
[TBL] [Abstract][Full Text] [Related]
36. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies.
Kennedy VE; Savani BN; Greer JP; Kassim AA; Engelhardt BG; Goodman SA; Sengsayadeth S; Chinratanalab W; Jagasia M
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1801-1807. PubMed ID: 27377900
[TBL] [Abstract][Full Text] [Related]
37. The Cape Town experience with haematopoietic stem cell transplantation: the paediatric programme.
Roux P; Novitzky N
S Afr Med J; 2000 Aug; 90(8):804-11. PubMed ID: 11022631
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
39. Outcome of hematopoietic stem cell transplantation (HCT) from HLA-matched related donor for Fanconi anemia (FA) in adolescents and adults: a retrospective study by Eastern Mediterranean Blood and Marrow Transplantation Group (EMBMT).
AlDawsari G; Elhaddad A; El Fakih R; Ben Othman T; Ahmed P; Ghavamzadeh A; Bazarbachi A; Dasouki MJ; Fathy G; Alzahrani H; Samra M; Torjemane L; Satti TM; Shaheen M; Alfraih F; Ayas M; Alahmari A; Alhayli S; Nassar A; Abboud M; Abdelfattah R; El Solh H; Hashmi S; Elhassan T; Ahmed SO; Aljurf M
Bone Marrow Transplant; 2020 Jul; 55(7):1485-1490. PubMed ID: 32024988
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning.
Torjemane L; Ladeb S; Ben Othman T; Abdelkefi A; Lakhal A; Ben Abdeladhim A
Pediatr Blood Cancer; 2006 Apr; 46(4):496-500. PubMed ID: 16333862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
